Zuclopenthixol
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Zuclopenthixol
- Pharmacist Assessment Report
- Zuclopenthixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Zuclopenthixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies
One-Sentence Summary
Zuclopenthixol is an antipsychotic originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but no clinical trials and no publications currently support this prediction, so it rests on the model’s computation alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, zuclopenthixol is a thioxanthene antipsychotic that antagonizes dopamine D1/D2 and 5-HT2A receptors, with additional alpha-1 and H1 activity. Its efficacy has been established in schizophrenia, a psychiatric condition.
No plausible mechanistic link to retinal dystrophy has been established. Retinal dystrophies are genetically heterogeneous inherited disorders, and nothing in the available data connects dopamine antagonism to their disease pathways. Phenothiazine-class drugs are also known to carry a risk of retinal toxicity (pigmentary retinopathy), which argues against benefit rather than for it.
The high TxGNN score (0.9999, rank 219) is a TxGNN model (deep learning) prediction only. It should be treated as a hypothesis-generating signal, not as evidence of efficacy.
Other predicted indications (all L5, all Hold):
| Rank | Predicted Indication | TxGNN Score | Comment |
|---|---|---|---|
| 2 | Hydranencephaly | 0.9999 | Congenital structural brain malformation; no rationale for a dopamine antagonist |
| 3 | Congenital disorder of glycosylation with defective fucosylation | 0.9999 | Enzymatic or metabolic defect unrelated to receptor antagonism |
| 4 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 0.9999 | Antipsychotic neurological adverse effects could complicate this population |
| 5 | Myopia, X-linked | 0.9999 | Retinal dopamine is involved in eye growth, but antagonism is expected to act in the unfavourable direction |
| 6 | Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 0.9999 | Congenital malformation syndrome; no plausible corrective role |
| 7 | Syndromic myopia | 0.9999 | Same weak, unfavourable dopamine link as above |
| 8 | Myopia 26, X-linked, female-limited | 0.9999 | Same weak, unfavourable dopamine link as above |
| 9 | Atypical glycine encephalopathy | 0.9999 | Antipsychotics may lower the seizure threshold, a concern in this population |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02230402 | CLOPIXOL | Not specified | Not specified |
| 02230403 | CLOPIXOL | Not specified | Not specified |
| 02230405 | CLOPIXOL ACUPHASE | Not specified | Not specified |
All three authorizations are valid single-ingredient products.
Safety Considerations
Please refer to the package insert for safety information.
No drug-drug interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score. There are no clinical trials or publications, and no mechanistic link between dopamine/5-HT2A antagonism and retinal dystrophy. The known risk of retinal toxicity with related drug classes points in the opposite direction.
To proceed, the following is needed:
- Mechanism of action data for zuclopenthixol (for example, from DrugBank)
- Health Canada package insert warnings and contraindications, which are required before any safety screening
- Preclinical or mechanistic evidence linking zuclopenthixol to retinal dystrophy pathways
- An assessment of ocular safety, given the retinal toxicity concern with related antipsychotics
- Approved indication text, dosage forms and manufacturers for the three Canadian authorizations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.